What it is
ARA-290, also called pHBSP, is an engineered peptide derived from the erythropoietin helix-B region and designed to study tissue-protective signaling without erythropoietic activity.
Mechanism and research questions
- Research focuses on tissue-protective signaling through an innate repair receptor complex.
- The intended separation from erythropoietic activity must be evaluated from the actual study and preparation.
Human evidence
Human trials have investigated specific neuropathy and metabolic endpoints; the evidence should not be generalized beyond those populations.
Preclinical / mechanistic evidence
Preclinical work examines inflammatory, neural, and tissue-protection models.
Evidence summary
Phase II studies and reviews exist for specific neuropathy and metabolic contexts, but this is not an approved general therapy.
Limits and interpretation
- Clinical evidence is indication-specific and limited.
- Do not infer erythropoietin-equivalent effects or safety.
- No dosing or human-use guidance is provided.
Regulatory and identity note
Investigational research peptide; not presented as approved therapy.